CareDx Announces Third KOAR Analysis Published in Transplantation
Business Wire•03/11/2026•07:05 ET
0
Key Highlights
- ➤1,137 recipients across 56 centers comprised the third KOAR analysis
- ➤Persistent AlloSure Kidney elevation linked to nine-fold higher graft-loss incidence
- ➤Late elevation associated with antibodies, rejection, and 8.8% graft loss
- ➤Transient elevations showed graft-loss incidence similar to consistently low levels
- ➤83.7% maintained low levels and favorable three-year outcomes
Expert Statements
Kalathil Sureshkumar, MD, FRCP, FASN, Division of Nephrology and Hypertension, Medicine Institute, Allegheny General Hospital
“Our findings show that the pattern of dd-cfDNA changes during the first four months after transplantation can predict long-term graft outcomes. Persistent or later-emerging elevations can identify patients at substantially higher risk of rejection and graft loss, while transient elevations that resolve are associated with more favorable outcomes. These findings reinforce the value of routine early monitoring to help clinicians identify patients who may benefit from closer surveillance.”
Jeffrey Teuteberg, MD, Chief Medical Officer of CareDx
“The robust evidence provided by the KOAR registry continues to demonstrate the utility of AlloSure Kidney across clinical contexts and throughout the post-transplant course.”
Jeffrey Teuteberg, MD, Chief Medical Officer of CareDx
“The routine use of AlloSure Kidney can help clinicians identify which patients early post-transplant may be at higher risk for poor outcomes and support development of personalized care strategies for these patients.”
CareDx Announces Third KOAR Analysis Published in Transplantation
AlloSure® Kidney trajectories within the first four months post-transplant were associated with three-year graft outcomes
Get started
Create a free account to read the full story.